Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized open-label study comparing daratumumab-based regimens in transplant-eligible newly diagnosed multiple myeloma
2018-002089-37Phase 2Active
- Sponsor
- European Myeloma Network
- Start
- Oct 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of daratumumab in multiple myeloma (MM) (2 arms), sponsored by European Myeloma Network. Primary endpoint: Progression-free survival. Started Oct 2018; status: active.
02
Drugs
daratumumab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2018-002089-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-002089-37.